Voluntary nationwide recall: Methocarbamol (Eugia - March)
Apr. 2024Pharmacy Updates
Eugia US LLC is recalling one lot of Methocarbamol Injection, USP 1000 mg/10 mL (100 mg/mL). Methocarbamol is used for the relief of discomfort from acute, painful musculoskeletal conditions.
This drug is being recalled because white particles were found in one vial during a customer’s inspection. Using an injectable product that contains particulate matter may cause local irritation or swelling. It may also block blood vessels, leading to life-threatening blood clot events.
As of the date of Eugia’s recall announcement, March 28, 2024, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below.
If you have an affected lot of Methocarbamol, you should stop using the item and return it to the place of purchase.
To learn more about this recall, you can take one or more of the steps below.
This drug is being recalled because white particles were found in one vial during a customer’s inspection. Using an injectable product that contains particulate matter may cause local irritation or swelling. It may also block blood vessels, leading to life-threatening blood clot events.
As of the date of Eugia’s recall announcement, March 28, 2024, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below.
If you have an affected lot of Methocarbamol, you should stop using the item and return it to the place of purchase.
To learn more about this recall, you can take one or more of the steps below.
- Talk to your doctor or pharmacist.
- Call Eugia US LLC at 866-850-2876, option 2. TTY users should call 711. Help is available Monday through Friday from 8 a.m. to 5 p.m. EST.
- Visit the FDA website.
Recent Announcements
Asymptomatic Severe Coronary Disease: Detection to Decisions. Do We Know The Proper Management?
In this new CME course, Krishna V. Tummalapalli, MD, interventional cardiologist, UPMC Heart and Vascular Institute, discusses how to explain the importance of early detection of coronary artery disease, as well as how to describe how early identification can reduce future cardiovascular events and identify appropriate first line medical therapy strategies for patients with asymptomatic stable ischemic heart disease.Mar. 2026Education/Webinars
CME Webinar Series: Introducing Physicians and their teams to Value-Based Health Care
Please join us for a new CME-accredited webinar series on value-based care. This series is designed to introduce practicing physicians and their teams to value-based health care. Over the course of six sessions, we will define the components of value and identify the tools necessary to deliver high-value care for a population.Feb. 2026Education/Webinars